Clinical Trials Logo

Filter by:
NCT ID: NCT04051489 Completed - Clinical trials for Osteoarthritis, Knee

A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials

Start date: September 3, 2019
Phase:
Study type: Observational

The overarching goal is to develop a mHealth App that can use smartphone embedded sensors to objectively collect physical function data in individuals with knee osteoarthritis (KOA) in the context of daily life.

NCT ID: NCT04050527 Completed - Clinical trials for Adult Lower Limb Spasticity

Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort

AboLiSh
Start date: December 19, 2019
Phase:
Study type: Observational

The purpose of the protocol is to assess the longitudinal attainment of person-centered and function related goals of patients who receive AbobotulinumtoxinA (aboBoNT-A) injections for adult lower limb spasticity over a period of 16 months.

NCT ID: NCT04048902 Completed - Low Back Pain Clinical Trials

Shortwave Diathermy and Pilates Exercises in Patients With Chronic Non-specific Low Back

Start date: March 6, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to verify the effectiveness of the association of Shortwave Diathermy and Pilates exercises in patients with chronic non-specific low back pain, on the reduction of pain, functional disability and improvement of the quality of life.

NCT ID: NCT04048018 Completed - Clinical trials for Latent Tuberculosis Infection

Performance Evaluation of the VIDAS TB-IGRA Assay.

Start date: December 5, 2019
Phase:
Study type: Observational

This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection. This study is designed to assess (1) the sensitivity of this assay, (2) its percent agreement with other diagnostic tests, (3) its measurement precision , and (4) any potential interference of the presence of other non-tuberculosis mycobacterial bacterial infections with this assay.

NCT ID: NCT04047914 Completed - Clinical trials for Renal Insufficiency, Chronic

Antimicrobial Photodynamic Therapy in the Nasal Decolonization of Maintenance Hemodialysis Patients

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

The objective of this study will be to evaluate the effect of Antimicrobial Photodynamic Therapy (aPDT) in the Nasal Decolonization of Dialytic Chronic Renal Patients, Staphylococcus Aureus (S.aureus) Carriers This is a 3-months follow-up, randomized, single-blind, prospective controlled trial, single-center and will happen in 02 phases: Phase 1 - Epidemiological Evaluation - A researcher will invite the research participants who are undergoing treatment at the Hemodialysis Service of Clinical Hospital and explain its contents. After reading and signing the informed consent, this same researcher (calibrated for the experiment) will perform nasal secretion microbiological collections to identify patients colonized by S.aureus in the anterior nostril (nasal carrier) - baseline T0 and the application of the questionnaire that identifies possible factors that may be considered as risk for colonization and possible development of diseases related to S. aureus. In the laboratory of Microbiology, the strains will be identified and the colonized patients will be invited to continue the study (Phase 2). Non-carrier patients will only be counseled with infection prevention care. Phase 2 - Parallel clinical trial with two intervention groups (aPDT or Mupirocin) - Patients with nasal aureus (thirty-four colonized patients aged over 18 years) will be treated with aPDT (experimental group) or mupirocin (control group). A trained researcher will collect new aliquots of nasal discharge after completion of nostril treatment (T1) to check for decolonization by culture. A new collection will be performed at 1 (T2) and 3 (T3) months after treatment to assess recolonization. It was evaluated intervention safety (photodynamic therapy) through a directed and open questionnaire about adverse effects.

NCT ID: NCT04044677 Completed - Cerebral Palsy Clinical Trials

Virtual Reality Therapy and Transcranial Direct Current Stimulation in Cerebral Palsy.

Start date: January 20, 2019
Phase: N/A
Study type: Interventional

A double-blinded randomized controlled crossover trial will be conducted, and all participants will undertake non-immersive VR tasks and tDCS-active or tDCS-sham. Group 1 will start with ten sessions of tDSC-active combined to VR tasks. After one-month washout, this group will be reallocated to another 10 sessions with tDCS-sham combined to VR tasks. In contrast, Group 2 will do the opposite protocol (participants will start allocated to ten sessions of TDCS-sham and VR tasks, and after one-month washout period will be reallocated to ten sessions of tDCS-active and VR tasks). All protocol will have the assessment of Autonomic Nervous System, through Heart Rate Variability Analysis.

NCT ID: NCT04044638 Completed - Blood Pressure Clinical Trials

Eight Week Strength Training Reduces Blood Pressure of Middle Age Women

Start date: March 5, 2018
Phase: N/A
Study type: Interventional

Introduction: Strength training (ST) is an important non-pharmacological means to reduce blood pressure (BP). Objective: To verify the pressure response of women after 8 weeks of ST. Method: Fourteen women were divided into young group (YG) and middle age (MAG) and submitted to ST for 8 weeks, lasting 60 minutes in 11 alternating exercises per segment with intensity of 12 to 13 on the subjective perception scale of effort. BP was verified at weeks 1, 4 and 8.

NCT ID: NCT04042740 Completed - HIV Infection Clinical Trials

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

PURGE-C
Start date: November 15, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks in acute hepatitis C (HCV)-infected participants, with or without HIV-1 coinfection.

NCT ID: NCT04037748 Completed - Healthy Clinical Trials

Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form

Start date: June 25, 2019
Phase: Phase 1
Study type: Interventional

The study was to verify if the test formulation of Levothyroxine sodium presents an equivalent rate and extension of absorption to the comparator formulation when administered with the same dosage and under fasting conditions and after baseline correction concentrations.

NCT ID: NCT04037709 Completed - Gingivitis Clinical Trials

Photodynamic Therapy in Patients With Gingivitis

Start date: November 9, 2020
Phase: N/A
Study type: Interventional

The hypothesis to be tested in this study is whether photodynamic therapy (PDT) could favor the decontamination of these areas, as the photosensitizer and light are capable of reaching areas that these instruments have difficulty accessing. In other words, the objective of this study is to evaluate the impact of PDT as an adjuvant treatment to scaling, considering clinical immunoregulatory in patients with gingivitis with the predisposing factor of the use of a fixed orthodontic appliance. A randomized, controlled, double-blind, split-mouth clinical study will include 17 patients. Patients will have their mouth divided into two groups: Control group (n = 17) - Scaling and Root Planing (SRP) + PDT placebo and Experimental group (n = 17) - SRP + PDT. In G2 will be used methylene blue 0.005%, λ = 660nm, 9J (joule) per inflamed site, irradiance = 3.5W / cm (watts/centimeter), radiant exposure = 318J / cm2. In G1 and G2 the scaling will be performed with the aid of the ultrasound. All participants will receive oral hygiene guidance (OHG) after to the end of the study. The clinical periodontal data to be analyzed: plaque index (PI), gingival index (GI) and probing depth (PD) and clinical level of insertion (CLI) by means of a periodontal probe. Crevicular fluid will be collected (from 8 pre-determined sites) for analysis of the IL-6 (interleukin), IL-1β, IL-8, TNF-α (tumor necrosis factor) and IL-10 cytokines, using the ELISA method.